AbbVie Inc (BSP:ABBV34)
R$ 55.4 0.76 (1.39%) Market Cap: 1.57 Til Enterprise Value: 1.86 Til PE Ratio: 49.77 PB Ratio: 36.99 GF Score: 82/100

Abbvie Inc at Wolfe Research Inaugural Healthcare Conference Transcript

Nov 06, 2019 / 02:30PM GMT
Release Date Price: R$19.38
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

All right. Good. Well, thank you for joining us for this session. We're up here with management from AbbVie, 3 members of the management team. Rick Gonzalez, who's the CEO and Chairman of the Board. He spent more than 30 years at Abbott and then later AbbVie, working in a variety of roles, commercial, R&D, manufacturing, being the big boss of the company. Mike Severino as well. He's Vice Chairman, President of AbbVie, responsible for R&D and other expanded roles within the organization. He joined the company in 2014. Prior to that, he was at Amgen and also Merck for a number of years. And Rob Michael, who's Executive Vice President and Chief Financial Officer. Prior to that, he held a variety of roles, both within AbbVie and the predecessor company, Abbott, where he joined in 1993.

So with this list of speakers, we can cover a lot of ground here, which is great. I thought maybe we'd start off talking about something that's timely and topical, not oncology yet and the data that came up. But we're going to talk about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot